You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
The company said it plans to use the proceeds of the offering for general corporate purposes.
The firm said its Focus::Myeloid NGS-based panel for myeloid malignancies provides information for diagnosis, prognosis, treatment, and risk stratification of patients.
The company's revenues saw strong growth on gains in its biopharma services and clinical services operations.
Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate.
The panel targets actionable markers in seven genes to provide information related to patient stratification, disease management, and treatment selection.
The test is a microarray-based assay that analyzes the expression of 2,000 genes to identify the most likely tissue of origin for 15 common tumor types.
The Rutherford, NJ-based cancer molecular diagnostics firm will use the proceeds for general corporate purposes.
CGI's biopharma services accounted for most of its revenues, but clinical services revenues were up 181 percent on the October acquisition of Response Genetics.
The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.
Researchers have sequenced the genome of "the Methuselah of freshwater fish."
The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.
In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.